Oppenheimer Asset Management Inc. Sells 3,862 Shares of Boston Scientific Corporation (NYSE:BSX)

Oppenheimer Asset Management Inc. decreased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 3.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 110,600 shares of the medical equipment provider's stock after selling 3,862 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Boston Scientific were worth $11,157,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Investment Management Corp VA ADV bought a new stake in shares of Boston Scientific in the 4th quarter worth about $25,000. Colonial Trust Co SC lifted its position in Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after buying an additional 260 shares in the last quarter. Sunbeam Capital Management LLC acquired a new position in Boston Scientific during the 4th quarter worth about $26,000. Ameriflex Group Inc. acquired a new position in Boston Scientific during the 4th quarter worth about $31,000. Finally, Fairway Wealth LLC acquired a new position in Boston Scientific during the 4th quarter worth about $36,000. Institutional investors own 89.07% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on BSX shares. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Truist Financial upped their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Evercore ISI upped their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Finally, Barclays upped their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Twenty-two research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $116.09.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the transaction, the executive vice president now directly owns 178,342 shares of the company's stock, valued at $18,347,824.96. This trade represents a 24.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the transaction, the chief executive officer now directly owns 1,476,882 shares of the company's stock, valued at $153,137,894.58. This represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Up 0.2%

Shares of BSX stock traded up $0.19 on Wednesday, reaching $104.31. The company had a trading volume of 5,691,604 shares, compared to its average volume of 6,585,876. The company has a 50-day moving average of $102.32 and a 200-day moving average of $99.33. Boston Scientific Corporation has a 12 month low of $71.88 and a 12 month high of $107.17. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. The stock has a market cap of $154.32 billion, a PE ratio of 76.14, a PEG ratio of 2.69 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The business had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same period in the prior year, the business earned $0.56 EPS. Boston Scientific's revenue for the quarter was up 20.9% compared to the same quarter last year. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.